CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 143 enrolled
Drug / intervention
misoprostolbiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02411916
NCT02411916N/ACompleted
CompareCT.gov

Effect of Adjunctive Misoprostol on Blood Loss at Vaginal Delivery

New York City Health and Hospitals Corporation·interventional·Posted Apr 8, 2015·Updated Sep 30, 2021

In Brief

A clinical study evaluating misoprostol for Postpartum Hemorrhage. Completed, enrolled 143 participants across 1 site.

Detailed Summary

This document defines the Clinical Investigation Protocol for a study designed to determine whether blood loss after spontaneous vaginal delivery is altered by the addition of misoprostol administration to the standard use of intravenous oxytocin after delivery. The protocol is an open-label randomized prospective trial to be carried out at Queens Hospital Center. Blood loss will be measured indirectly by comparing the maternal hemoglobin and hematocrit levels on admission in labor to those obtained within 24 hours after delivery.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPostpartum Hemorrhage
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
First PostedApr 8, 2015
Enrollment StartMar 30, 2012
Primary CompletionFeb 16, 2019
TodayJul 2, 2026
Enrollment to primary: 6.9 yearsPosted 11.2 years ago

Interventions

misoprostolbiological

rectal insertion